Orion

Orion EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Orion (271560.KS) as of Oct 13, 2026 is 558.26 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 574.52 B KRW — a change of -2.83% (lower).

EBITDA

558.26 BKRW

YoY

-2.83%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Orion is 2025 558.26 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Orion was 2024 574.52 B KRW. It decreases by -2.83% lower compared to the previous year.

The Orion EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
298.78 B KRW
Jan 1, 2019
353.35 B KRW
Jan 1, 2020
404.14 B KRW
Jan 1, 2021
402.61 B KRW
Jan 1, 2022
498.34 B KRW
Jan 1, 2023
522.85 B KRW
Jan 1, 2024
574.52 B KRW
Jan 1, 2025
558.26 B KRW
The Orion EBITDA history
YEAREBITDAYoY
558.26 BKRW-2.83%
574.52 BKRW+9.88%
522.85 BKRW+4.92%
498.34 BKRW+23.78%
402.61 BKRW-0.38%
404.14 BKRW+14.38%
353.35 BKRW+18.26%
298.78 BKRW+153.97%
117.64 BKRW—
Access this data via the Eulerpool API

Orion Stock analysis

What does Orion do? Orion Corp is a Finnish company that operates in the pharmaceutical industry. The company was founded in 1917 and is headquartered in Espoo, Finland. Orion Corp specializes in the development, manufacturing, and marketing of medications, as well as the diagnosis and treatment of diseases. As one of the leading pharmaceutical companies in Finland, Orion Corp is dedicated to researching and developing medications and medical devices to help doctors and their patients worldwide improve their quality of life. Orion Corp's business model focuses on selling prescription and over-the-counter medications, as well as manufacturing generic medications. Additionally, the company is involved in the diagnosis and treatment of diseases such as Parkinson's, cancer, and asthma. The company's main business is centered around three main divisions: pharmaceuticals, diagnostics, and animal health. Within these divisions, Orion Corp has various business areas. In the pharmaceutical division, the focus is on developing medications to combat Parkinson's, cancer, and asthma. The company has a strong product range of Parkinson's treatments that can alleviate symptoms and slow the progression of the disease. Furthermore, the company is involved in the development of cancer medications that can inhibit the growth of cancer cells. Orion Corp is also a key player in asthma treatment. The company produces medications that expand the airways and make breathing easier. In the diagnostics division, Orion Corp's main business is the development and manufacturing of diagnostic devices for diseases such as lung cancer and asthma, as well as products for monitoring blood sugar and cholesterol. Animal health is another important business area for Orion Corp. The company manufactures medications and accessories for animal health and offers a variety of products to veterinarians and breeders. These include, for example, animal vaccines or hormone preparations to increase fertility in animals. Orion's production facilities are located in six countries, including Finland, Germany, France, Russia, the USA, and India. Production within the company primarily takes place in Finland. In addition to manufacturing medications and medical devices, Orion Corp is also a leading producer and developer of raw materials and intermediates for pharmaceutical applications worldwide. In summary, Orion Corp offers a wide range of products and services in the health and animal health fields using the latest scientific knowledge and technologies. The company remains committed to continuously expanding its product and service portfolio and providing patients worldwide with high-quality and effective medications that positively impact their lives. Orion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orion stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Orion is 558.26 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Orion changed from 574.52 B KRW to 558.26 B KRW, representing a -2.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Orion since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Orion historically and in real time.

Access this data via the Eulerpool API

Income Statement — Orion

All Key Metrics — Orion